World Investment Advisors Boosts Stock Holdings in Pfizer Inc. (NYSE:PFE)

World Investment Advisors lifted its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 14.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 153,435 shares of the biopharmaceutical company's stock after buying an additional 19,057 shares during the quarter. World Investment Advisors' holdings in Pfizer were worth $3,888,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of PFE. Brighton Jones LLC grew its holdings in Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after purchasing an additional 618,117 shares during the period. Revolve Wealth Partners LLC grew its holdings in shares of Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after buying an additional 2,087 shares during the last quarter. Inceptionr LLC acquired a new position in shares of Pfizer during the fourth quarter valued at about $229,000. Candriam S.C.A. grew its holdings in shares of Pfizer by 7.7% during the fourth quarter. Candriam S.C.A. now owns 422,501 shares of the biopharmaceutical company's stock valued at $11,209,000 after buying an additional 30,207 shares during the last quarter. Finally, Callan Family Office LLC acquired a new position in shares of Pfizer during the fourth quarter valued at about $595,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Price Performance

Shares of Pfizer stock traded down $0.13 during trading on Wednesday, hitting $25.49. The stock had a trading volume of 27,522,323 shares, compared to its average volume of 41,783,802. The firm has a market cap of $144.92 billion, a price-to-earnings ratio of 18.47, a P/E/G ratio of 0.92 and a beta of 0.58. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The business's 50-day moving average is $23.80 and its 200 day moving average is $24.81.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The firm's revenue was down 7.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.82 earnings per share. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 6.75%. Pfizer's payout ratio is 124.64%.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. Bank of America lifted their price objective on shares of Pfizer from $26.00 to $27.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Leerink Partners reduced their price objective on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a report on Wednesday, April 30th. Berenberg Bank dropped their price target on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research report on Thursday, May 29th. TD Cowen dropped their price target on shares of Pfizer from $32.00 to $28.00 and set a "hold" rating on the stock in a research report on Tuesday, April 22nd. Finally, Guggenheim reissued a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer has an average rating of "Hold" and a consensus target price of $28.55.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.